UPDATE-
SQZ Biotechnologies announces publication of review on APCs 16:49 SQZ SQZ Biotechnologies announced the publication of a technical review examining the ability of SQZ Antigen Presenting Cells, or APCs, to activate CD8 T cells through MHC-I antigen presentation, an approach that may enable a more powerful T cell response and infiltration into solid tumors. Published in ESMO's Immuno-Oncology and Technology, or IOTECH, journal, the review further explores the advantages of the company's Cell Squeeze technology in cell engineering and manufacturing as well as potential opportunities to develop additional clinical candidates with enhanced capabilities. The Cell Squeeze engineering method has compelling features compared to viral or electroporation approaches across a number of categories, including cell perturbation, scalability, cell types, cargo types, targeting, dosage control, and cost per dose. SQZ's approach has demonstrated preclinically dramatic improvements in potential CD8 T cell activation as well as synergy with next generation immuno-oncology drugs such as PD-1 IL2v. SQZ clinical candidates experienced an average vein-to-vein time of roughly one week, faster than most other therapeutic approaches for delivering sterile cell therapy.
SQZ Biotechnologies announces publication of review on APCs 16:49 SQZ SQZ Biotechnologies announced the publication of a technical review examining the ability of SQZ Antigen Presenting Cells, or APCs, to activate CD8 T cells through MHC-I antigen presentation, an approach that may enable a more powerful T cell response and infiltration into solid tumors. Published in ESMO's Immuno-Oncology and Technology, or IOTECH, journal, the review further explores the advantages of the company's Cell Squeeze technology in cell engineering and manufacturing as well as potential opportunities to develop additional clinical candidates with enhanced capabilities. The Cell Squeeze engineering method has compelling features compared to viral or electroporation approaches across a number of categories, including cell perturbation, scalability, cell types, cargo types, targeting, dosage control, and cost per dose. SQZ's approach has demonstrated preclinically dramatic improvements in potential CD8 T cell activation as well as synergy with next generation immuno-oncology drugs such as PD-1 IL2v. SQZ clinical candidates experienced an average vein-to-vein time of roughly one week, faster than most other therapeutic approaches for delivering sterile cell therapy.
